Market Overview

UPDATE: Jefferies & Company Terminates Coverage on Biosante Pharmaceuticals

Related BPAX
BioSante Hires VP of New Business Development and Contract Manufacturing and Announces New Appointment to Board of Directors
Stocks Hitting 52-Week Lows

In a report published Friday, Jefferies & Company terminated its coverage on Biosante Pharmaceuticals (NASDAQ: BPAX).

Jefferies noted, “Due to a reallocation of resources, we are dropping coverage of BioSante Pharmaceuticals (BPAX). Our last rating on BioSante was Hold with a $2 price target...Our $2 PT was based on a DCF taken out to 2026, discounted at 20%. Our most recent published risks included the potential for additional dilutive financings and pipeline setbacks.”

Biosante Pharmaceuticals closed on Friday at $1.30.

Latest Ratings for BPAX

DateFirmActionFromTo
Oct 2012Jefferies & CompanyDrops Coverage on

View More Analyst Ratings for BPAX
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Termination Analyst Ratings

 

Related Articles (BPAX)

Around the Web, We're Loving...

Get Benzinga's Newsletters